BAM
KNSA icon

Belpointe Asset Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Belpointe Asset Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$237K Buy
+3,709
New +$192K 0.01% 988
2023
Q2 		– Sell
-1,200
Closed -$12.9K – 2070
2023
Q1 		$12.9K Hold
1,200
– – ﹤0.01% 2567
2022
Q4 		$18K Buy
+1,200
New +$17.5K ﹤0.01% 2260

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Belpointe Asset Management's KNSA Position: Q2 2026 in Review

Belpointe Asset Management opened a new position in Kiniksa Pharmaceuticals (KNSA) in Q2 2026: 3,709 shares worth $237K. The stake represents 0.01% of the portfolio and ranks #988 among its holdings. This is a return to the name: Belpointe Asset Management previously reported a position in KNSA as recently as Q1 2023.

Belpointe Asset Management first reported a position in KNSA in Q4 2022 and has held it in 3 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Belpointe Asset Management held 3,709 shares of Kiniksa Pharmaceuticals worth $237K as of Q2 2026.
  • Kiniksa Pharmaceuticals was a new Belpointe Asset Management position in Q2 2026.
  • Kiniksa Pharmaceuticals made up 0.01% of Belpointe Asset Management's portfolio in Q2 2026, its #988 holding.
  • Belpointe Asset Management first reported a position in Kiniksa Pharmaceuticals in Q4 2022 and has held it in 3 quarters since.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Belpointe Asset Management's 13F filing for Q2 2026, filed 31 Jul 2026.